^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    VPREB1 (V-Set Pre-B Cell Surrogate Light Chain 1)

    i
    Other names: VPREB1, V-Set Pre-B Cell Surrogate Light Chain 1, CD179 Antigen-Like Family Member A, Immunoglobulin Iota Chain, Pre-B Lymphocyte 1, V(Pre)B Protein, VPREB, Protein VPreB1, CD179a Antigen, VpreB Protein, CD179a, CD179A, IGVPB, VpreB, IGI
    3ms
    Establishment and characterization of a novel cell line ICH-BCPALL-3 from B cell precursor acute lymphoblastic leukemia with TCF3::HLF. (PubMed, Hum Cell)
    The cytotoxicity assay indicated that the cell line is sensitive to Aurora Kinase B inhibitor, but not to BCL2 inhibitor. This cell line is the first TCF3::HLF-positive BCP-ALL model without the t(17;19) translocation, facilitating research into leukemogenesis and the development of novel treatments for patients with poor prognosis associated with TCF3::HLF-positive BCP-ALL.
    Preclinical • Journal • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • PAX5 (Paired Box 5) • TCF3 (Transcription Factor 3) • NCOR1 (Nuclear Receptor Corepressor 1) • AURKB (Aurora Kinase B) • VPREB1 (V-Set Pre-B Cell Surrogate Light Chain 1) • ARID5B (AT-Rich Interaction Domain 5B)
    |
    CDKN2A deletion • RB1 deletion
    7ms
    An antibody-drug conjugate targeting VpreB1 for the treatment of B-cell acute lymphoblastic leukemia. (PubMed, Blood Neoplasia)
    When tested against a B-ALL cell line and multiple B-ALL patient-derived xenograft models, the VpreB1-ADC significantly reduced leukemia burden, prolonged survival, and cured a subset of mice. These promising results support further investigation of the VpreB1 component of the surrogate light chain as a therapeutic target, including the VpreB1-ADC in preclinical and clinical trials, with the goal of expanding the arsenal of immunoconjugates available for the treatment of B-ALL.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule) • VPREB1 (V-Set Pre-B Cell Surrogate Light Chain 1)
    9ms
    Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab. (PubMed, J Hematol Oncol)
    WBC ≥ 70 × 109/L is a high-risk feature in patients with Ph + ALL receiving frontline blinatumomab and ponatinib and may supersede the prognostic importance of baseline molecular features. Alternative frontline treatment strategies may be needed for these patients to reduce the risk of relapse and improve long-term outcomes.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • CD19 (CD19 Molecule) • IKZF1 (IKAROS Family Zinc Finger 1) • VPREB1 (V-Set Pre-B Cell Surrogate Light Chain 1)
    |
    Iclusig (ponatinib) • Blincyto (blinatumomab)
    over1year
    Construction of a five-gene-based prognostic model for relapsed/refractory acute lymphoblastic leukemia. (PubMed, Hematology)
    We have developed a risk prediction model for pediatric R/R ALL utilizing the genes BAG2, EPHA4, FBXO9, SNX10, and WNK1. This model provides a scientific foundation for early identification of R/R ALL in children.
    Journal • IO biomarker
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • SOX2 • CD27 (CD27 Molecule) • CD3D (CD3d Molecule) • LCK (LCK Proto-Oncogene, Src Family Tyrosine Kinase) • WNK1 (WNK Lysine Deficient Protein Kinase 1) • CD3G (CD3 Gamma Subunit Of T-Cell Receptor Complex) • NANOG (Nanog Homeobox) • RASGRP1 (RAS Guanyl Releasing Protein 1) • VPREB1 (V-Set Pre-B Cell Surrogate Light Chain 1) • BLNK (B Cell Linker) • E2F1 (E2F transcription factor 1) • EPHA4 (EPH Receptor A4) • FBXO9 (F-Box Protein 9) • HOXB4 (Homeobox B4)
    over1year
    Application of Gene Expression Microarray for the Classification of Ph-Like B-Cell Acute Lymphoblastic Leukemia. (PubMed, Int J Lab Hematol)
    In summary, we demonstrate using a gene expression microarray for classifying Ph-like B-cell ALL and highlight VPREB1 as a potential biomarker for this disease.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • ABL1 (ABL proto-oncogene 1) • JAK1 (Janus Kinase 1) • CA6 (Carbonic Anhydrase 6) • CD9 (CD9 Molecule) • EPHA7 (EPH Receptor A7) • TCL1A (TCL1 Family AKT Coactivator A) • VPREB1 (V-Set Pre-B Cell Surrogate Light Chain 1)
    |
    ABL1 fusion
    over1year
    Characterisation of cells markers associated with IKZF1plus in BCP-ALL. (PubMed, Transl Oncol)
    In this scenario, we found associations between IKZF1plus and certain genes in BCP-ALL, being KCNA5 and GREB1 the most promising biomarkers for predicting IKZF1plus. A deeper understanding of these genetic profiles will allow a better risk assessment and offer precise rationale for therapeutic strategies in BCP-ALL.
    Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • IKZF1 (IKAROS Family Zinc Finger 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • PAX5 (Paired Box 5) • CD200 (CD200 Molecule) • BTLA (B And T Lymphocyte Associated) • SDK1 (Sidekick Cell Adhesion Molecule 1) • VPREB1 (V-Set Pre-B Cell Surrogate Light Chain 1)
    |
    CDKN2A deletion • IKZF1 deletion • VPREB1 deletion
    almost2years
    A multiomic characterization of the leukemia cell line REH using short- and long-read sequencing. (PubMed, Life Sci Alliance)
    Whole-genome sequencing clarified the molecular traits of disrupted ALL-associated genes including CDKN2A, PAX5, BTG1, VPREB1, and TBL1XR1, as well as the glucocorticoid receptor NR3C1 Meanwhile, transcriptome sequencing identified seven fusion genes within the genomic breakpoints. Together, our extensive whole-genome investigation makes high-quality open-source data available to the leukemia genomics community.
    Preclinical • Journal
    |
    CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6) • PAX5 (Paired Box 5) • VPREB1 (V-Set Pre-B Cell Surrogate Light Chain 1) • TBL1XR1 (TBL1X Receptor 1)
    almost2years
    Comparative analysis of dynamic transcriptomes reveals specific COVID-19 features and pathogenesis of immunocompromised populations. (PubMed, mSystems)
    Our observed differential genes/complexes and clinical indicators of normal/long infection and deceased COVID-19 patients provide clues for understanding the mechanism of COVID-19 progression in hematological tumors. Finally, our study provides an important data resource that supports the increasing value of the application of publicly accessible data sets to public health.
    Journal
    |
    SERPINE1 (Serpin Family E Member 1) • APOE (Apolipoprotein E) • VPREB1 (V-Set Pre-B Cell Surrogate Light Chain 1) • IGLL1 (Immunoglobulin Lambda Like Polypeptide 1)
    over2years
    Functional Diversification and Dynamics of CAR-T Cells in B-ALL Patients (ASH 2023)
    Correspondence to Drs. Zongcheng Li, Bing Liu, Lilin Ye, Yu Lan and Liang Huang.
    Clinical • CAR T-Cell Therapy • IO biomarker
    |
    GZMB (Granzyme B) • GZMH (Granzyme H) • GZMK (Granzyme K) • VPREB1 (V-Set Pre-B Cell Surrogate Light Chain 1)
    over2years
    Atypical Stem Cell, Pre-B-Cell, T-Cell and Myeloid Gene Expression Characterizes Early Waldenstrom's Macroglobulinemia Clones Which Diminishes with Advancing Disease and Has Therapeutic Implications (ASH 2023)
    This analysis suggests that stem cell program reactivation and atypical marker expression characterize early WM clones that are ultimately replaced by clones exhibiting more typical B-cell markers with disease progression. The findings may be relevant to treatment selection and provide a framework for investigating subtype and early/late evolutionary staging in the treatment approach to WM.
    IO biomarker
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD8 (cluster of differentiation 8) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CD33 (CD33 Molecule) • CD34 (CD34 molecule) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CD14 (CD14 Molecule) • CD27 (CD27 Molecule) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • PRDM1 (PR/SET Domain 1) • VPREB1 (V-Set Pre-B Cell Surrogate Light Chain 1) • XBP1 (X-box-binding protein 1) • CEACAM8 (CEA Cell Adhesion Molecule 8) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • RAG1 (Recombination Activating 1) • IGLL1 (Immunoglobulin Lambda Like Polypeptide 1)
    |
    MYD88 mutation • CD19 expression • CD33 expression
    over2years
    Early Subclones Showing Aberrant Co-Expression of Stem Cell, T Cell and Myeloid Genes Can be Detected By Flow Cytometry in MYD88 Mutated Waldenström's Macroglobulinemia Patients (ASH 2023)
    In WM primary cells, we observed the existence of a clonal B cell population that appears to re-activate stem cell programming early on and progressively is replaced by clones bearing more typical B cell markers with disease expansion. This study lays the foundation to develop a widely accessible methodology to accurately diagnose IgM MGUS/early-stage WM and monitor disease evolution. Flow-based sorting of these subclones will allow targeted multi-omic studies with insights into disease pathogenesis and targeted therapeutic applications.
    Clinical
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD8 (cluster of differentiation 8) • CD33 (CD33 Molecule) • CD34 (CD34 molecule) • SDC1 (Syndecan 1) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • PRDM1 (PR/SET Domain 1) • VPREB1 (V-Set Pre-B Cell Surrogate Light Chain 1) • XBP1 (X-box-binding protein 1) • CEACAM8 (CEA Cell Adhesion Molecule 8) • IGLL1 (Immunoglobulin Lambda Like Polypeptide 1)
    |
    MYD88 mutation • KIT expression